购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

Regorafenib

产品编号 T1792Cas号 755037-03-7
别名 BAY 73-4506, 瑞戈非尼, Fluoro-Sorafenib, 瑞格非尼

Regorafenib (BAY 73-4506) 是一种多靶点受体酪氨酸激酶抑制剂,抑制 RET、C-RAF、VEGFR2、c-Kit、VEGFR1 和 PDGFRβ (IC50=1.5/2.5/4.2/7/13/22 nM),具有口服活性。Regorafenib 具有抗肿瘤和抗血管生成活性。

Regorafenib

Regorafenib

纯度: 99.95%
产品编号 T1792 别名 BAY 73-4506, 瑞戈非尼, Fluoro-Sorafenib, 瑞格非尼Cas号 755037-03-7

Regorafenib (BAY 73-4506) 是一种多靶点受体酪氨酸激酶抑制剂,抑制 RET、C-RAF、VEGFR2、c-Kit、VEGFR1 和 PDGFRβ (IC50=1.5/2.5/4.2/7/13/22 nM),具有口服活性。Regorafenib 具有抗肿瘤和抗血管生成活性。

规格价格库存数量
5 mg¥ 192现货
10 mg¥ 298现货
25 mg¥ 515现货
50 mg¥ 788现货
100 mg¥ 1,230现货
200 mg¥ 1,850现货
500 mg¥ 3,130现货
1 mL x 10 mM (in DMSO)¥ 358现货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多

"Regorafenib"的相关化合物库

选择批次:
纯度:99.95%
联系我们获取更多批次信息
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性
产品描述
Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ and is orally active. Regorafenib has antitumor and anti-angiogenic activity.
靶点活性
VEGFR2:4.2 nM (cell free), VEGFR1:13 nM (cell free), c-Kit:7 nM (cell free), B-Raf (V600E):19 nM (cell free), RET:1.5 nM (cell free), Raf-1:2.5 nM (cell free)
体外活性
方法:人肝癌细胞 Hep3B、PLC/PRF/5 和 HepG2 用 Regorafenib (0-10 μM) 处理 72 h,使用 MTT 方法检测细胞活力。
结果:Regorafenib 浓度依赖性降低 Hep3B 细胞活力,IC50 约为 5 μM。PLC/PRF/5 细胞的敏感性与 Hep3B细胞相似。但 HepG2 细胞更敏感,IC50 约为 1 μM。[1]
方法:肿瘤细胞 NIH-3T3/VEGFR2、CHO/TIE2、HAoSMC/PDGFR-β 和 MCF-7/FGFR 用 Regorafenib (10-3000 nM) 处理 1 h,使用 Western Blot 方法检测靶点蛋白表达水平。
结果:Regorafenib 抑制 p-VEGFR2、p-TIE2、p-PDGFR-β 和 p-FGFR。[2]
体内活性
方法:为检测体内抗肿瘤活性,将 Regorafenib (3-100 mg/kg) 口服给药给携带肿瘤 Colo-205 或 MDA-MB-231 的 NCr nu/nu 小鼠,每天一次,持续九天。
结果:Regorafenib 抑制肿瘤生长。Colo-205 模型中,Regorafenib 在 10 mg/kg 的剂量下,第 14 天的 TGI 达到 75%。MDA-MB-231 模型,Regorafenib 在低至 3 mg/kg 的剂量下是高效的,导致 81% 的显著TGI。[2]
方法:为检测体内抗肿瘤活性,将 Regorafenib (3-10 mg/kg) 口服给药给携带肿瘤 HT-29 或 MDA-MB-231 的 NMRI nu/nu 小鼠,每天一次,持续二十七天。
结果:Regorafenib 剂量依赖性抑制 HT-29 和 MDA-MB-231 肿瘤生长。[3]
激酶实验
In vitro assays using recombinant VEGFR2 (murine aa785–aa1367), VEGFR3 (murine aa818–aa1363), PDGFR-b (aa561–aa1106), RAF-1 (aa305–aa648) and BRAFV600E (aa409–aa765) kinase domains were performed as previously described. Initial in vitro kinase inhibition profiling was performed at a fixed 1 μM compound concentration under Millipore standard conditions [10 μM adenosine-50'- triphosphate (ATP) concentration]. Inhibitory concentration of 50% (IC50) values were determined from selected responding kinases, e.g., VEGFR1 and RET. TIE2 kinase inhibition was measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate.
细胞实验
Each cell line was seeded at 0.3×10^5 cells/2ml of DMEM containing 10% FBS in 35 mm tissue culture dishes. The cells were incubated for 24 h to allow attachment, and then the medium was replaced by fresh culture medium containing Regorafenib at increasing concentrations (1 μM, 2.5 μM, 5 μM, 7.5 μM and 10 μM). In these experimental conditions, the cells were allowed to grow for 72 or 96 h. Time-course experiments on Hep3B cells were performed with 7.5 μM of Regorafenib at short (15, 60, 180 min.), middle (24, 48, 72 and 96 h) or long times (up to seven days). When the cells were treated for long times the drug was replaced with a fresh one. Each experiment included a control with the equivalent concentration of DMSO (solvent control) as the one used for adding Regorafenib. Each experiment was performed in triplicate and repeated 3 times. Subsequent analyses were performed at specific Regorafenib concentrations and incubation times [2].
动物实验
Female athymic NCr nu/nu mice, kept in accordance with Federal guidelines, were subcutaneously inoculated with 5×10^6 Colo-205 or MDAMB-231 cells or implanted with 1 mm^3 786-O tumor fragments. When tumors reached a volume of ~100 mm^3, regorafenib or vehicle control was administered orally qd×21 in the 786-O model, and qd×9 in the Colo-205 and MDA-MB231 models, respectively, at doses of 100, 30, 10, and 3 mg/kg. Paclitaxel was administered intravenously at 10 mg/kg in ethanol/Cremophor ELV/saline (12.5%/12.5%/75%) every 2 days×5. Tumor size (volume) was estimated twice weekly (l×w^2)/2, and the percentage of tumor growth inhibition (TGI) was obtained from terminal tumor weights (1-T/C100). Mice were weighed every other day starting from the first day of treatment. The general health status of the mice was monitored daily [1].
别名BAY 73-4506, 瑞戈非尼, Fluoro-Sorafenib, 瑞格非尼
化学信息
分子量482.82
分子式C21H15ClF4N4O3
CAS No.755037-03-7
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
DMSO: 60 mg/mL (124.27 mM)
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 9 mg/mL (18.64 mM), Suspension. Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
溶液配制表
10% DMSO+40% PEG300+5% Tween 80+45% Saline/DMSO
1mg5mg10mg50mg
1 mM2.0712 mL10.3558 mL20.7117 mL103.5583 mL
5 mM0.4142 mL2.0712 mL4.1423 mL20.7117 mL
10 mM0.2071 mL1.0356 mL2.0712 mL10.3558 mL
DMSO
1mg5mg10mg50mg
20 mM0.1036 mL0.5178 mL1.0356 mL5.1779 mL
50 mM0.0414 mL0.2071 mL0.4142 mL2.0712 mL
100 mM0.0207 mL0.1036 mL0.2071 mL1.0356 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

Related Tags: buy Regorafenib | purchase Regorafenib | Regorafenib cost | order Regorafenib | Regorafenib chemical structure | Regorafenib in vivo | Regorafenib in vitro | Regorafenib formula | Regorafenib molecular weight